Key Takeaways
- • Roseman Wagner Wealth Management (RWWM) accumulated nearly 17% of Carter's Inc. (NYSE: CRI) shares, making it the retailer's largest shareholder, triggering a defensive response from the board.
- • Carter's board adopted a shareholder rights plan (poison pill) in October 2025 to prevent an unsolicited takeover, with the plan set to expire approximately one year from implementation.
- • The hedge fund's accumulation occurred without advance notice to Carter's management, and despite management's attempts to contact RWWM, the firm did not respond or provide communication regarding its strategic intentions.
- • Carter's is executing a turnaround strategy initiated in May 2025 under new leadership; the company has faced persistent operational challenges since the pandemic and has not achieved positive comparable sales since 2019.
- • The poison pill mechanism allows Carter's to issue preferred share purchase rights to existing shareholders on October 3, 2025, designed either to dilute a hostile acquirer's stake or improve negotiating leverage if the company becomes open to acquisition.
Summary
Hedge fund Roseman Wagner Wealth Management disclosed in mid-September 2025 that it had acquired approximately 17% of Carter's Inc., positioning itself as the children's apparel retailer's largest shareholder. The rapid and undisclosed nature of the stock accumulation prompted Carter's board of directors to adopt a shareholder rights plan—commonly known as a poison pill—on September 24, 2025, according to financial filings with federal regulators.
Carter's management stated it received no advance notice of RWWM's share purchases and had made unsuccessful attempts to contact the hedge fund regarding its intentions. In its regulatory filing, the company noted that "it is possible that RWWM is continuing to accumulate stock," indicating uncertainty about whether the hedge fund planned further acquisitions. RWWM declined to respond to media inquiries about its strategic objectives or future plans for its stake in the retailer.
The poison pill structure operates as follows: on October 3, 2025, Carter's will issue one preferred share purchase right to each outstanding shareholder of record. This defensive mechanism reduces the probability of an unsolicited takeover or, if shareholders approve an acquisition, strengthens the company's negotiating position to secure a higher purchase price. The shareholder rights plan has a one-year expiration window, providing the board time to respond to RWWM's actions or negotiate a potential transaction.
The timing of RWWM's investment coincides with Carter's mid-turnaround under new executive leadership. The company unveiled a strategic restructuring plan in May 2025 but continues to face material headwinds. According to Wells Fargo analysts, Carter's has encountered "continual challenges since the pandemic" and, despite implementing a new pricing strategy, has failed to achieve positive comparable-store sales since 2019. The retailer reported mixed Q2 results, with strength in U.S. wholesale operations offset by weakness in U.S. retail and international segments.
The hedge fund's significant stake and passive approach—marked by silence rather than activism—leaves the retailer's strategic future uncertain, with the poison pill providing a temporary shield while the board assesses RWWM's ultimate objectives and Carter's options for value creation or defending against takeover attempts.
Carter's management stated it received no advance notice of RWWM's share purchases and had made unsuccessful attempts to contact the hedge fund regarding its intentions. In its regulatory filing, the company noted that "it is possible that RWWM is continuing to accumulate stock," indicating uncertainty about whether the hedge fund planned further acquisitions. RWWM declined to respond to media inquiries about its strategic objectives or future plans for its stake in the retailer.
The poison pill structure operates as follows: on October 3, 2025, Carter's will issue one preferred share purchase right to each outstanding shareholder of record. This defensive mechanism reduces the probability of an unsolicited takeover or, if shareholders approve an acquisition, strengthens the company's negotiating position to secure a higher purchase price. The shareholder rights plan has a one-year expiration window, providing the board time to respond to RWWM's actions or negotiate a potential transaction.
The timing of RWWM's investment coincides with Carter's mid-turnaround under new executive leadership. The company unveiled a strategic restructuring plan in May 2025 but continues to face material headwinds. According to Wells Fargo analysts, Carter's has encountered "continual challenges since the pandemic" and, despite implementing a new pricing strategy, has failed to achieve positive comparable-store sales since 2019. The retailer reported mixed Q2 results, with strength in U.S. wholesale operations offset by weakness in U.S. retail and international segments.
The hedge fund's significant stake and passive approach—marked by silence rather than activism—leaves the retailer's strategic future uncertain, with the poison pill providing a temporary shield while the board assesses RWWM's ultimate objectives and Carter's options for value creation or defending against takeover attempts.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.